Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Apparatus and formulations for suprachoridal drug delivery

a technology of suprachoridal and appendix, which is applied in the field of eye drug delivery, can solve the problems of limiting treatment options, affecting the access to the eye for medical treatment, and the delicate nature of the tissues, so as to prevent trauma

Inactive Publication Date: 2013-09-19
CLEARSIDE BIOMEDICAL
View PDF3 Cites 66 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes devices and methods for delivering drugs to the eye's suprachoroidal space. These devices include a needle with a special tip that can pass through the sclera tissue without damaging the choroid tissue. Additionally, some devices have a sensor to help guide the placement of the tip for maximum accuracy. The technical effect of this invention is to provide a minimally invasive and safe method for delivering drugs to the eye's suprachoroidal space.

Problems solved by technology

Accessing the eye for medical treatment is hindered by the small size and delicate nature of the tissues.
The posterior region of the eye, including the retina, macula and optic nerve, is especially difficult to access due to the recessed position of the eye within the orbital cavity.
In addition, topical eye drops penetrate poorly into the posterior region, further restricting treatment options.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Apparatus and formulations for suprachoridal drug delivery
  • Apparatus and formulations for suprachoridal drug delivery
  • Apparatus and formulations for suprachoridal drug delivery

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0054]Fluorescent dyed polystyrene microspheres (Firefli™, Duke Scientific, Inc., Palo Alto, Calif.) suspended in phosphate-buffered saline were used as model drug to evaluate the size range in which particulates will migrate in the suprachoroidal space from the anterior region to the posterior region.

[0055]An enucleated human cadaver eye was radially incised to the choroid in the pars plana region, which is in the anterior portion of the eye. Using a syringe terminated with a blunt 27 gauge needle, 0.15 mL of a 1% by volume microsphere suspension (mean diameter 6 micron) was delivered into the anterior region of the suprachoroidal space. The needle was withdrawn and the incision sealed with cyanoacrylate adhesive.

[0056]The eye was then perfused for 24 hours with phosphate buffered saline at 10 mm Hg pressure by introducing into the anterior chamber a 30 gauge needle attached to a reservoir via infusion tubing. The reservoir was placed on a lab jack and elevated to provide constant ...

example 2

[0059]The experiment of Example 1 was repeated, except that a mixture of 6 and 33 micron diameter fluorescent microspheres as a model drug was suspended in a polymeric excipient comprising a surgical viscoelastic (Healon 5, Advanced Medical Optics, Inc.), a 2.3% concentration of sodium hyaluronic acid of 4,000,000 Daltons molecular weight, with thixotropic properties of a zero shear viscosity of 7,000,000 mPas and 400 mPas viscosity at 1000 s−1 shear rate. The mixture was introduced into the suprachoroidal space in the manner of Example 1. After 24 hour perfusion, the microspheres resided solely in the suprachoroidal space at the anterior instillation site and did not show evidence of migration, demonstrating the localizing effect of the thixotropic polymeric excipient.

example 3

[0060]To demonstrate the effect of polymeric excipient viscosity on drug localization, the experiment of Example 1 was repeated, except that bevacizumab (Avastin™, Genentech), an anti-VEG antibody, was adsorbed onto 5 micron diameter carboxylated fluorescent microspheres and mixed at equal volumes with one of three hyaluronic acid based surgical viscoelastics (Healon, Healon GV, Healon 5, Advanced Medical Optics, Inc.), each with a different viscosity and thixotropic properties. (Healon, 300,000 mPas viscoscity at zero shear rate, 150 mPas viscosity at 1000 s-1 shear rate; Healon GV, 3,000,000 mPas viscosity at zero shear rate, 200 mPas at 1000 s-1 shear rate; Healon 5, 7,000,000 mPas viscosity at zero shear rate, 400 mPas viscosity at 1000 s-1 shear rate.) Each mixture was introduced into the anterior region of the suprachoroidal space at the pars plana in the anterior region of the eye in the manner of Example 1. After 24 hours perfusion, the microspheres in Healon and Healon GV w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This is a continuation of U.S. Ser. No. 11 / 709,941, filed Feb. 21, 2007, which, in turn, claims the priority of provisional U.S. Ser. No. 60 / 776,903, filed Feb. 22, 2006, pursuant to 35 USC 119(e). The prior applications are incorporated herein by reference in their entirety for all purposes.FIELD OF THE INVENTION[0002]The invention relates to the field of drug delivery into the eye.BACKGROUND OF INVENTION[0003]The eye is a complex organ with a variety of specialized tissues that provide the optical and neurological processes for vision. Accessing the eye for medical treatment is hindered by the small size and delicate nature of the tissues. The posterior region of the eye, including the retina, macula and optic nerve, is especially difficult to access due to the recessed position of the eye within the orbital cavity. In addition, topical eye drops penetrate poorly into the posterior region, further restricting treatment options.[0004]The ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61F9/00
CPCA61K9/0048A61K9/1635A61K31/717A61K31/718A61K31/722A61F9/0017A61K31/737A61K47/10A61K47/32A61K47/36A61M5/31501A61K31/728A61K9/0051A61K9/14A61K9/50A61K31/716A61K38/39A61F9/00736A61M5/486A61M2005/3103A61M2210/0612A61F9/0026A61F9/007
Inventor YAMAMOTO, RONALDCONSTON, STANLEY R.SIERRA
Owner CLEARSIDE BIOMEDICAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com